Cargando…

Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis

BACKGROUND: The purpose of this study was to detect the efficacy and safety of tacrolimus (TAC) in induction therapy of patients with lupus nephritis. METHODS: Associated studies were extracted from the PubMed and the Cochrane Library on July 10, 2018, and applicable investigations were pooled and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tianbiao, Lin, Shujun, Yang, Shen, Lin, Wenshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420100/
https://www.ncbi.nlm.nih.gov/pubmed/30880918
http://dx.doi.org/10.2147/DDDT.S189156
_version_ 1783404056736169984
author Zhou, Tianbiao
Lin, Shujun
Yang, Shen
Lin, Wenshan
author_facet Zhou, Tianbiao
Lin, Shujun
Yang, Shen
Lin, Wenshan
author_sort Zhou, Tianbiao
collection PubMed
description BACKGROUND: The purpose of this study was to detect the efficacy and safety of tacrolimus (TAC) in induction therapy of patients with lupus nephritis. METHODS: Associated studies were extracted from the PubMed and the Cochrane Library on July 10, 2018, and applicable investigations were pooled and analyzed by meta-analysis. Data on complete remission (CR), total remission (TR; complete plus partial remission), proteinuria levels, urine erythrocyte number, albumin, glomerular filtration rate, negative rate of ds-DNA, C(3) levels, C(4) levels, systemic lupus erythematosus disease activity index (SLE-DAI), etc, were extracted and pooled using RevMan 5.3. RESULTS: In the therapeutic regimen of TAC + glucocorticoids (GC) vs cyclophosphamide (CYC) + GC, the results indicated that the TAC group had high values of CR, TR, albumin, and negative rate of ds-DNA, and low values of proteinuria levels and SLE-DAI when compared with those in CYC group (all P<0.05). In the therapeutic regimen comprising TAC + GC vs mycophenolate mofetil (MMF) + GC, the results indicated that the difference of CR, TR, proteinuria levels, and albumin between TAC group and MMF group were not significant (all P>0.05). In the therapeutic regimen comprising TAC + MMF + GC vs CYC + GC, multitarget therapy group showed higher values of CR, TR, urinary protein decline, and rise of serum albumin when compared with CYC group (all P<0.05). CONCLUSION: TAC is an effective and safe agent in induction therapy of patients with lupus nephritis.
format Online
Article
Text
id pubmed-6420100
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64201002019-03-16 Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis Zhou, Tianbiao Lin, Shujun Yang, Shen Lin, Wenshan Drug Des Devel Ther Original Research BACKGROUND: The purpose of this study was to detect the efficacy and safety of tacrolimus (TAC) in induction therapy of patients with lupus nephritis. METHODS: Associated studies were extracted from the PubMed and the Cochrane Library on July 10, 2018, and applicable investigations were pooled and analyzed by meta-analysis. Data on complete remission (CR), total remission (TR; complete plus partial remission), proteinuria levels, urine erythrocyte number, albumin, glomerular filtration rate, negative rate of ds-DNA, C(3) levels, C(4) levels, systemic lupus erythematosus disease activity index (SLE-DAI), etc, were extracted and pooled using RevMan 5.3. RESULTS: In the therapeutic regimen of TAC + glucocorticoids (GC) vs cyclophosphamide (CYC) + GC, the results indicated that the TAC group had high values of CR, TR, albumin, and negative rate of ds-DNA, and low values of proteinuria levels and SLE-DAI when compared with those in CYC group (all P<0.05). In the therapeutic regimen comprising TAC + GC vs mycophenolate mofetil (MMF) + GC, the results indicated that the difference of CR, TR, proteinuria levels, and albumin between TAC group and MMF group were not significant (all P>0.05). In the therapeutic regimen comprising TAC + MMF + GC vs CYC + GC, multitarget therapy group showed higher values of CR, TR, urinary protein decline, and rise of serum albumin when compared with CYC group (all P<0.05). CONCLUSION: TAC is an effective and safe agent in induction therapy of patients with lupus nephritis. Dove Medical Press 2019-03-12 /pmc/articles/PMC6420100/ /pubmed/30880918 http://dx.doi.org/10.2147/DDDT.S189156 Text en © 2019 Zhou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhou, Tianbiao
Lin, Shujun
Yang, Shen
Lin, Wenshan
Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
title Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
title_full Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
title_fullStr Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
title_full_unstemmed Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
title_short Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
title_sort efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420100/
https://www.ncbi.nlm.nih.gov/pubmed/30880918
http://dx.doi.org/10.2147/DDDT.S189156
work_keys_str_mv AT zhoutianbiao efficacyandsafetyoftacrolimusininductiontherapyofpatientswithlupusnephritis
AT linshujun efficacyandsafetyoftacrolimusininductiontherapyofpatientswithlupusnephritis
AT yangshen efficacyandsafetyoftacrolimusininductiontherapyofpatientswithlupusnephritis
AT linwenshan efficacyandsafetyoftacrolimusininductiontherapyofpatientswithlupusnephritis